Article Details
Retrieved on: 2023-11-22 21:02:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The U.S. Food and Drug Administration (FDA) granted Agili-C Breakthrough Device designation status in 2020 and Premarket Approval (PMA) in March 2022.
Article found on: orthospinenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here